Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy (PONV)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2013 by San-Hui Lee, National Health Insurance Service Ilsan Hospital.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
San-Hui Lee, National Health Insurance Service Ilsan Hospital Identifier:
First received: December 10, 2013
Last updated: December 12, 2013
Last verified: December 2013

To compare postoperative nausea and vomiting (PONV) and perioperative outcomes of gynecologic patients undergoing laparoscopic surgery after scheduled administration of intravenous Ramosetron during hospital stays.

  • Randomized controlled arm : Placebo versus Ramosetron injection
  • Administration schedule : immediate postoperative status, 12 hrs after surgery, 36hrs after surgery

Condition Intervention Phase
Uterine Myoma, Ovary Neoplasm, Adenomyosis
Drug: Ramosetron
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy

Resource links provided by NLM:

Further study details as provided by San-Hui Lee, National Health Insurance Service Ilsan Hospital:

Primary Outcome Measures:
  • Incidence or intensity of PONV [ Time Frame: during postoperative hospital stays (2 days) ]

Secondary Outcome Measures:
  • Adverse reaction associated with Ramosetron injection [ Time Frame: Postoperatvie 7 days (at OPD based) ]

Estimated Enrollment: 128
Study Start Date: November 2013
Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ramosetron Drug: Ramosetron

Detailed Description:
Surgical outcomes including operative time, blood loss, Hb change, postoperative pain, nausea/vomiting scale, times of rescue therapy, and complications

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age: 18< or =, = or <70 with benign gynecologic disease
  • ASA-Class I-II
  • No-definite malignancy by US, CT/MRI, CA 125 < 500IU/ml
  • Non-smoker

Exclusion Criteria:

  • Conversion to laparotomy
  • Hx of malignancy
  • Smoker
  • Suspicious malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02011659

Contact: San-Hui Lee, M.D. +82-900-0218

Korea, Republic of
National Health Insurance Service Ilsan Hospital Recruiting
Goyang-si, Korea, Republic of, 410-719
Principal Investigator: San-Hui Lee, M.D.         
Sponsors and Collaborators
National Health Insurance Service Ilsan Hospital
  More Information

Responsible Party: San-Hui Lee, Clinical assistant professor, National Health Insurance Service Ilsan Hospital Identifier: NCT02011659     History of Changes
Other Study ID Numbers: PONV-NHIS-GYN-001
Study First Received: December 10, 2013
Last Updated: December 12, 2013

Keywords provided by San-Hui Lee, National Health Insurance Service Ilsan Hospital:
Ramosetron, postoperative nausea and vomiting, laparoscopy

Additional relevant MeSH terms:
Ovarian Neoplasms
Signs and Symptoms, Digestive
Signs and Symptoms
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Connective Tissue Diseases
Uterine Diseases
Genital Diseases, Female
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents processed this record on May 25, 2017